Vaxart, Inc. · OTC:VXRT
Vaxart — SVB Leerink 2020 CyberRx Call Series
24 slides from Vaxart's conference presentation, Sep 23, 2020
Slide 1: The Pill Against COVID-19
Slide 2: Forward-looking statements
emen ‘This presentation contains forwardtocking statements that involve substantial risks and uncertainties, Al statements, other than statements of historical facts, Included inthis presentation regarding Vaxart's strategy, prospects, plans and objectives, results from precncal and clinical al, com
Slide 3: Transformative Oral Vaccine Platform
01 Transformative Oral Vaccine Platform Potential to disrupt the vaccine ecosystem 02 Oral COVID-19 Program may offer the Best Practical Global Solution to Pandemic (Oral convenience, potential superior efficacy due to mucosal immunity, ease of distribution ~ room temp. stable SWI} 03 Validated Clin
Slide 4: No needles, no waste
no needles, otentiall otective than injectable vaccines: activates mucosal immunity - the first line of defense, plus multiple immune system mechanisms no needles, no waste
Slide 5: Convenient, painless, self-administered
mo Convenient, painless, self-administered Facilitates social distancing during a pandemic ‘Appealing to those who dislike injections & needles + 1-2months to vaccinate large populations with injectables + 23days with a pill 1-19 + No medical personnel needed + No vaccination centers needed
Slide 6: Vaccine hesitancy and needle aversion
doctor's office are the main reasons why 2017/18 US FLU VACCINATION BY AGE Vaccinated ot US Population ‘As few as 50% of people inthe United States are committed to te vaccine, with another quarter waverin ing a Less than half of American adults say they would get a goverment-approved coronavirus va
Slide 7: Cold chain and distribution challenges
SGA + No refrigeration for storage ~ major cost & space savings + No refrigeration for distribution — significantly simpler & cheaper, eliminates potential bottlenecks + Can be sipped cheaply to any corner of the US or the Globe Cold Chain: very complex & expensive ture requirements “wil make it ver
Slide 8: Oral vaccine activates the mucosal immune system
Vaxart’s oral vaccine activates the mucosal immune system: the 1* line of defense against airborne viruses Oral vaccine activates immunity in the right places Vaxart’s oral vaccine triggers a broad immune response, activating systemic and mucosal immunity: Mouth Nose Lungs Intestine Injectable vacci
Slide 9: Flu: Vaxart pill likely to protect better than injectable
rbor 1e virus: Vaxart pill likely to protect injectable in BARDA-funded clinical trial ven e Phase II trial comparing Vaxart’s oral tablet vaccine and Sanofi’s Fluzone injectable flu vaccine tection Against Illness % of subjects without symptoms 39% kites THE LANCET Results Infectious Diseases _ in
Slide 10: Preventing infection altogether
preventing infection altogether Phase II trial comparing Vaxart’s oral tablet vaccine and Sanofi’s Fluzone injectable flu vaccine By triggering a strong enough mucosal immunity, Vaxart’s oral vaccine has the potential to prevent infection altogether Protection Against Infection % of subjects not inf
Slide 11: Tolerability comparison in BARDA-funded flu study
bility Comp: 8 BARDA-funded flu stud Anysmptomstoteted) _Painatjeconste Tenderness at njectonste 2% jam Laie jaccine sag sie basse a ; ~ os Poin: a key reason for which people don’ lke needles Source: Uebowtetal Lancet nets Deas, Jon 2020,
Slide 12: Vaxart vaccine contains both the S and N genes from SARS-CoV-2
Slide 13: Full-length S better for creating neutralizing antibody responses
Full-length S better for creating neutralizing antibody responses IgG antibody titers to Covid St eVNT vs SVNT ELISA Technology a 4 Endpoint ELISA ter Moore, et al, BioRxiv, 2020
Slide 14: COVID vaccine induces lung antibody responses, IgA and neutralizing antibodies
Vaxart COVID vaccine induces lung antibody responses, IgA and neutralizing antibodies Lung IgA titers to $1 or S2 Lung Antibody Titer, SVNT — 4000. +1000. eA est 0.0317 ° “82 wlE 1 10. . IgA endpoint titre FAG-S-NrAd-S1-N TAGSN AGSIN neg Group Moore, et al, BioRxiv, 2020
Slide 15: T cell responses to S
IFN-y Spots /1x108 Cells. 600: 200: IFN-g T cell Responses to S * v AA * + neg etl 16 te FAL-S.N te Frequency of (CD8+ CD4d+ T cells, (CD8+ IFNgt 18
Slide 16: Well tolerated vaccine platform
Well tolerated vaccine platform Potent immune responses even at low vaccine doses Mucosal Immunity might be really important + Both mucosal IgA and mucosal T cells have been shown to contribute to sterilizing immunity in other respiratory diseases + Can't be adequately addressed by an injected vacci
Slide 17: Comparison with other COVID-19 vaccine technologies
Technology Limitations Likely Immune Needles Cold chain CanSinoBio rAdS injected Az/ Oxford Chimp rAd Antivector Immunity nAb, T cells Yes Yes Janssen TAd26 injected DNA/RNA ‘Moderna Stabilized RNA New technol Ab ¥. Ye Pfizer/BioNTech RNA ewer " “ ° Novavax Insect cell culture Only makes Ab Ab Yes Y
Slide 18: Simpler manufacturing process than for injectables
1@ KindredBio Simpler manufacturing process than for injectables: - No sterile fill and finish No need for vials
Slide 19: COVID-19 program milestones
September 2 2020 3 potential Candidate for Candidate Selected USIND cleared covip-19 ‘human trials for the US Operation Cesc als vaccines built selected Warp Speed NHP started for ph! study - — >< » clinical Key manufacturing Additional studies partnerships Pre-clinical established studies
Slide 20: Pipeline including prophylactic and therapeutic programs
includes prophylactic and Ket aa a iit utc ae ee swe cowio-19 = eres Sega une seal cncet, 1) iatent rate demonsited gh SC reponse of 0 B9K fr Gland 78-86 or GL 2} Monoralen fs yzene conoid shave 2 Poot Cone effec sy 5} Sansien coloration wth anoptenteneqotte ene sense. 5) tevibespeucpeinbtettacncaee
Slide 21: Vaxart is the leading oral vaccine biotechnology company
Vaxart is the leading oral vaccine biotechnology company emit Kindoasio AMS fh G Sant former fle f
Slide 22: Experience in Vaccines
Exp erience in Vaccines i agenus anv paved Do\ ~ @GENTERIC ‘System © uARD SCHWART2, PHO . — Techical Opera fox hil Medimmune [fy =s""" SRAILYJAINE GARG : <foeke) Genentech ohitey “Geneon mur ee Ep merck = DYNAVAX MARGARET EOHERD,CPAMGA. align E extreme Quotient
Slide 23: Transformative Oral Vaccine Platform
01 Transformative Oral Vaccine Platform Potential to disrupt the vaccine ecosystem 02 Oral COVID-19 Program may offer the Best Practical Global Solution to Pandemic (Oral convenience, potential superior efficacy due to mucosal immunity, ease of distribution ~ room temp. stable SWI} 03 Validated Clin
Slide 24: Slide 24